Get the Stockscreener App
35.72
2.75%
-1.01
Pre-market:
36.30
0.58
+1.62%
Hemab Therapeutics Holdings Inc stock is traded at $35.72, with a volume of 401.28K.
It is down -2.75% in the last 24 hours and down -23.46% over the past month.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
See More
Previous Close:
$36.73
Open:
$36.89
24h Volume:
401.28K
Relative Volume:
0.93
Market Cap:
$1.67B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-43.91
EPS:
-0.8135
Net Cash Flow:
-
1W Performance:
-13.34%
1M Performance:
-23.46%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$34.01
$37.64
1-Week Range:
$34.01
$43.20
52-Week Range:
$23.00
$55.42
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
Name
Hemab Therapeutics Holdings Inc
Sector
Industry
Phone
45 2138 7627
Address
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
35.72 | 1.67B | 0 | 0 | 0 | -0.8135 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hemab Therapeutics Holdings Inc Stock (COAG) Latest News
Keli Walbert elected to Hemab board, joins Audit Committee - TradingView
Hemab Therapeutics Holdings, Inc. (COAG) stock price, news, quote and history - Yahoo Finance UK
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert - The Manila Times
Hemab Therapeutics (NASDAQ:COAG) Shares Down 5.7%What's Next? - MarketBeat
Hemab Therapeutics Holdings, Inc.(NasdaqGS:COAG) added to S&P Biotechnology Select Industry Index - marketscreener.com
Hemab Therapeutics Holdings, Inc.(NasdaqGS: COAG) added to S&P Global BMI Index - marketscreener.com
Hemab Therapeutics Holdings, Inc.(NasdaqGS:COAG) added to Russell 3000 Value Benchmark - marketscreener.com
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding - The Manila Times
Heavy menstrual bleeding affects 1 in 3 women. Hemab begins testing a new treatment. - Stock Titan
Hemab Therapeutics (COAG) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Shares Up 7.6%Time to Buy? - MarketBeat
Opaleye Management Inc. Makes New Investment in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Trading Down 6.8%What's Next? - MarketBeat
Citadel Advisors LLC Takes Position in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Braidwell LP Purchases New Shares in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Biopharma IPO class of 2026: share price up 66% on average - BioWorld News
Hemab Therapeutics (NASDAQ:COAG) Trading Down 8.4%Here's What Happened - MarketBeat
AppLovin vs. CoreWeave: What Recent Revenue Trends Tell Investors - Yahoo Finance
Capital International Investors Establishes New Position in Hema - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Novo Holdings A/S (COAG) discloses 9.0% beneficial stake in Hemab Therapeutics - Stock Titan
Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake - Stock Titan
20 Years of Prix Galien USA Brings a New Nominee Class—Who Wins? - Stock Titan
HC Wainwright Cuts Earnings Estimates for Hemab Therapeutics - MarketBeat
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64 - Moomoo
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Hemab Therapeutics (COAG): Capital International Investors discloses 7.7% ownership - Stock Titan
Hemab Therapeutics stock price target raised to $60 by H.C. Wainwright - Investing.com Canada
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
FMR LLC Acquires Stake in Hemab Therapeutics Holdings Inc (COAG) - GuruFocus
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Hemab Therapeutics Reports Q2 2026 Financials and Pipeline Progress in Latest 10-Q Filing - Kalkine Media
Hemab Therapeutics (COAG) widens loss but builds $457.5M cash war chest - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating - marketscreener.com
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com South Africa
Hemab Therapeutics Gains FDA Backing to Advance Sutacimig Into Phase 3 Trial for Glanzmann Thrombasthenia - Minichart
Hemab Therapeutics' Q2 Net Loss Narrows - marketscreener.com
Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss - marketscreener.com
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Hemab Therapeutics reports Q2 2026 net loss of $24.2M, cash runway into 2029 after $317M IPO proceeds - TradingView
Hemab Unveils Peptide-Based Approach to Heavy Menstrual Bleeding - Stock Titan
Hemab Therapeutics (NASDAQ: COAG) investors detail 5.1% passive ownership stake - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Hits New 1-Year HighTime to Buy? - MarketBeat
FMR LLC reports 7.9% Hemab Therapeutics (COAG) stake on Schedule 13G - Stock Titan
Sofinnova group (NASDAQ: COAG) discloses 5.4% Hemab Therapeutics ownership on Schedule 13G - Stock Titan
SUTNTIB AB Tewox publishes its NAV for July 2026 - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Trading Down 4.8%What's Next? - MarketBeat
CCC Intelligent Solutions Holdings Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Hemab Therapeutics Holdings Inc Stock (COAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):